Genelux Corporation (GNLX)

Market Cap	77.76M
Revenue (ttm)	8,000
Net Income (ttm)	-27.66M
Shares Out	34.10M
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,860
Open	2.300
Previous Close	2.270
Day's Range	2.160 - 2.310
52-Week Range	1.600 - 16.600
Beta	n/a
Analysts	Strong Buy
Price Target	18.25 (+700.44%)
Earnings Date	Nov 14, 2024

About GNLX

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 2023
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: GNLX
• Website: https://www.genelux.com

Financial Performance

In 2023, Genelux's revenue was $170,000, a decrease of -98.46% compared to the previous year's $11.07 million. Losses were -$28.30 million, 443.4% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for GNLX stock is "Strong Buy." The 12-month stock price forecast is $18.25, which is an increase of 700.44% from the latest price.

Price Target

$18.25

(700.44% upside)

Analyst Consensus: Strong Buy